Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.40 +0.14 (+0.55%)
Official Closing Price Updated: 4:10 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 46,477,891
Open 25.33
Bid (Size) 25.42 (8)
Ask (Size) 25.43 (34)
Prev. Close 25.26
Today's Range 25.20 - 25.54
52wk Range 25.23 - 40.36
Shares Outstanding 5,606,688,356
Dividend Yield 6.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program. 
Via Benzinga
Exposures Product Safety

Performance

YTD
-14.56%
-14.56%
1 Month
-7.94%
-7.94%
3 Month
-7.54%
-7.54%
6 Month
-18.49%
-18.49%
1 Year
-34.25%
-34.25%

More News

Read More
Pfizer's Options: A Look at What the Big Money is Thinking
Via Benzinga
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
Via The Motley Fool
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
Via Investor's Business Daily
Exposures Product Safety
Creative Biolabs: The Way ADCs Are Made Has Changed
Via Get News
US Stock: Pfizer
Via Talk Markets
Pfizer Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
From Pfizer Inc.
Via Business Wire
What's Going On With Pfizer Stock On Thursday?
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 Bargain Stocks Near 52-week Lows
Via MarketBeat
Topics Economy
Exposures Interest Rates
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Pfizer Declares Second-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
The Top 7 Dividend Stocks to Buy in 2024 to Build Lasting Wealth
Via InvestorPlace
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Via InvestorPlace
3 Defensive Stocks To Protect Your Portfolio In 2024
Via Talk Markets
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
Via InvestorPlace
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
Via The Motley Fool
3 Blue-Chip Stocks That Will Beat Index Returns Over the Next 3 Years
Via InvestorPlace
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
From Pfizer Inc.
Via Business Wire
Capturing Consumer Spending on Health Care with XLV
Via News Direct
3 Stocks Under $50 You Can Buy Hand Over Fist Right Now
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.